ERBB3 and breast cancer: Lapatinib, a dual TKI targeting EGFR and HER2, induces feedback upregulation at the mRNA and protein levels in BC cell lines, and HER3 knockdown restores the drug sensitivity of lapatinib-resistant cells [59].